This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves - Report - MDSpire

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

  • May 26, 2026

Share

Clinical Report: Merck TROP2 ADC Meets Phase 3 Endpoints in Endometrial Cancer

Overview

Merck's investigational TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), has met its dual primary endpoints of overall survival and progression-free survival in a phase 3 trial for advanced or recurrent endometrial cancer.

Background

Endometrial cancer treatment has evolved significantly, particularly for patients who have progressed after platinum-based chemotherapy and anti-PD-1/L1 therapy. The introduction of novel therapies, such as antibody-drug conjugates, represents an advancement in managing this patient population.

Data Highlights

EndpointOutcome
Overall SurvivalMet
Progression-Free SurvivalMet

Key Findings

  • Sac-TMT met dual primary endpoints of overall survival and progression-free survival.
  • The trial involved patients with advanced or recurrent endometrial cancer after prior platinum and anti-PD-1/L1 therapy.
  • This is the first positive phase 3 readout from Merck’s TroFuse program.
  • The study compared sac-TMT against physician’s choice chemotherapy.
  • Merck has 17 ongoing global phase 3 trials across multiple tumor types.

Clinical Implications

The findings from the TroFuse-005 trial may provide a new treatment option for patients with advanced or recurrent endometrial cancer who have limited alternatives. Clinicians should consider the implications of these results in the context of evolving treatment guidelines.

Conclusion

The successful outcomes of the TroFuse-005 trial highlight the potential of sac-TMT as a viable therapeutic option in advanced endometrial cancer. Continued research and trials will be essential to further validate these findings.

Related Resources & Content

  1. Merck, FDA, 2026 -- FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma
  2. NCI, Endometrial Cancer Treatment (PDQ®) - NCI, 2025 -- Endometrial Cancer Treatment (PDQ®)
  3. PubMed, Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025, 2025 -- Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025
  4. the medicine maker — This Week’s Biopharma News: Amgen Deepens US Manufacturing Push
  5. Ophthalmology Management — Quick Notes: January 24, 2024 Recommendations
  6. the medicine maker — Biopharma’s Survival Moment
  7. the medicine maker — The New Path to ADCs
  8. FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma | FDA
  9. Endometrial Cancer Treatment (PDQ®) - NCI
  10. Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025 - PubMed

Original Source(s)

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

  • May 26, 2026

Related Content

Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health

Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...

Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...

2026 NCCN Clinical Practice Guidelines in Oncology®: Key Updates Across Tumor Types

The National Comprehensive Cancer Network® (NCCN®) first introduced the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, initially covering eight tumor types. Three decades la...